The lawsuit, filed by the Rosen Law Firm, centers on claims that Insulet failed to disclose critical deficiencies in its manufacturing procedures. According to the complaint, these internal lapses created a foreseeable risk that the company’s medical products would violate safety regulations or jeopardize patient health. Plaintiffs allege that because these risks remained hidden, the company's public statements during the class period were materially false, leading to financial losses for shareholders when the details surfaced.

Investors who held PODD stock during this window are eligible to join the litigation, which operates on a contingency fee basis. While the court has yet to certify a class, those wishing to influence the direction of the case must file a motion by August 31, 2026. Participation as a lead plaintiff is not required to benefit from a potential future settlement, and investors retain the right to select their own legal representation.